RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dongkook Pharmaceutical Co Stock

Dongkook Pharmaceutical Co Stocks 2024

Dongkook Pharmaceutical Co Stocks

44.73 M

Ticker

086450.KQ

ISIN

KR7086450004

In 2024, Dongkook Pharmaceutical Co had 44.73 M outstanding stocks, a 0% change from the 44.73 M stocks in the previous year.

The Dongkook Pharmaceutical Co Stocks history

YEARNUMBER OF STOCKS (undefined KRW)
2026e44.73
2025e44.73
2024e44.73
202344.73
202244.72
202144.72
202045
201945
201844
201744
201644
201544
201444
201344
201244

Dongkook Pharmaceutical Co shares outstanding

The number of shares was Dongkook Pharmaceutical Co in 2023 — This indicates how many shares 44.731 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dongkook Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dongkook Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dongkook Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dongkook Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dongkook Pharmaceutical Co Aktienanalyse

What does Dongkook Pharmaceutical Co do?

Dongkook Pharmaceutical Co Ltd is a South Korean company that specializes in the development and manufacturing of pharmaceutical products. It was founded in 1968 by Choon-kyu Kim, who was working in the research department of Pfizer at the time and wanted to start his own company. During the early years, Dongkook focused on the formulation of drugs and medications manufactured by other companies. In the 1980s, Dongkook expanded its business and started developing and manufacturing its own products. A new facility was also built in Bucheon, a suburb of Seoul, during this time. Production focused on prescription medications, particularly cardiovascular drugs and antidiabetic agents. Dongkook became one of the leading companies in South Korea in this area. In the 1990s, Dongkook continued its expansion and began focusing on the Asian market. New markets were tapped into and partnerships with other pharmaceutical companies were established. In 2000, Dongkook went public, providing additional capital. Today, Dongkook is a globally operating company with a wide portfolio of medications and healthcare products. The company is divided into various business segments, including cardiovascular, diabetes, gastrointestinal, and dermatology. Each of these segments encompasses a wide range of products, from prescription drugs to over-the-counter dietary supplements. In the cardiovascular segment, Dongkook offers pharmaceuticals for the treatment of conditions such as heart failure, hypertension, and angina pectoris. The diabetes segment includes medications for the treatment of type 2 diabetes and other metabolic disorders. In the gastrointestinal segment, Dongkook produces medications for the treatment of stomach and intestinal problems, as well as for supporting the digestive system. In dermatology, the company manufactures medications for the treatment of skin diseases and cosmetic products. An important focus of Dongkook is the research and development of new innovative products. The company has its own research and development department, where work is done on new medications and technologies. Through close collaboration with other companies and research institutions around the world, Dongkook has been able to develop numerous products that are distinguished by their high quality and effectiveness. Dongkook is also committed to promoting sustainable and environmentally friendly business practices. The company is dedicated to the use of renewable energies and continuously works on measures to reduce its environmental impact. Additionally, the company is an active member of the community and supports numerous social initiatives, such as donation campaigns for non-profit organizations, educational programs, and environmental conservation projects. In summary, Dongkook Pharmaceutical Co Ltd is a leading global pharmaceutical company known for its innovation, product quality, and sustainable business practices. With a wide portfolio of medications and healthcare products, as well as a strong research and development department, the company is well-positioned for the future and will continue to play an important role in the pharmaceutical industry. Dongkook Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Dongkook Pharmaceutical Co's Shares Outstanding

Dongkook Pharmaceutical Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Dongkook Pharmaceutical Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Dongkook Pharmaceutical Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Dongkook Pharmaceutical Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Dongkook Pharmaceutical Co stock

How many stocks are there of Dongkook Pharmaceutical Co?

The current number of stocks of Dongkook Pharmaceutical Co is 44.73 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Dongkook Pharmaceutical Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Dongkook Pharmaceutical Co evolved in recent years?

The number of shares of Dongkook Pharmaceutical Co has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Dongkook Pharmaceutical Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Dongkook Pharmaceutical Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Dongkook Pharmaceutical Co pay?

Over the past 12 months, Dongkook Pharmaceutical Co paid a dividend of 180 KRW . This corresponds to a dividend yield of about 1.08 %. For the coming 12 months, Dongkook Pharmaceutical Co is expected to pay a dividend of 196.06 KRW.

What is the dividend yield of Dongkook Pharmaceutical Co?

The current dividend yield of Dongkook Pharmaceutical Co is 1.08 %.

When does Dongkook Pharmaceutical Co pay dividends?

Dongkook Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Dongkook Pharmaceutical Co?

Dongkook Pharmaceutical Co paid dividends every year for the past 15 years.

What is the dividend of Dongkook Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 196.06 KRW are expected. This corresponds to a dividend yield of 1.17 %.

In which sector is Dongkook Pharmaceutical Co located?

Dongkook Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dongkook Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dongkook Pharmaceutical Co from 4/19/2024 amounting to 180 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did Dongkook Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Dongkook Pharmaceutical Co in the year 2023?

In the year 2023, Dongkook Pharmaceutical Co distributed 180 KRW as dividends.

In which currency does Dongkook Pharmaceutical Co pay out the dividend?

The dividends of Dongkook Pharmaceutical Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dongkook Pharmaceutical Co

Our stock analysis for Dongkook Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dongkook Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.